Literature DB >> 17520682

Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma.

Chun-Ye Zhang1, Li Mao, Lei Li, Zhen Tian, Xiao-Jian Zhou, Zhi-Yuan Zhang, Jiang Li.   

Abstract

BACKGROUND: The role of promoter methylation in the inactivation of E-cadherin (E-cad) in salivary gland adenoid cystic carcinoma (ACC) is unknown. The objective of this study was to determine the role and potential clinical implications of promoter methylation of E-cad in salivary gland ACC.
METHODS: The promoter methylation status of E-cad was determined by using methylation-specific polymerase chain reaction (PCR) analysis in 60 primary salivary gland ACC tissues and 3 ACC cell lines. The level of E-cad protein expression was determined by immunohistochemical analysis of each tumor. E-cad protein and messenger RNA (mRNA) expression levels were examined by immunohistochemical analysis and reverse transcriptase-PCR in 3 ACC cell lines. Associations between molecular alterations and patients' clinicopathologic characteristics were analyzed statistically. E-cad mRNA expression was examined in a 5-azacytidine-treated ACC-2 cell line.
RESULTS: Promoter methylation of E-cad was detected in 34 of 60 tumors (57%). Of those 34 tumors, 18 tumors (53%) showed no E-cad protein expression, whereas only 5 of the remaining 26 tumors (19%) without E-cad promoter methylation showed no E-cad protein expression (P = .01). Tumors that had E-cad promoter methylation had a significantly higher histologic grade (P = .01) and more perineural invasion (P = .02) compared with tumors that did not have methylation. All 3 ACC cell lines exhibited E-cad promoter methylation and a lack of E-cad mRNA and protein expression, whereas 5-azacytidine restoredE-cad mRNA expression in the ACC-2 cell line.
CONCLUSIONS: E-cad frequently is inactivated in salivary gland ACC through promoter methylation, and E-cad promoter methylation may play a role in tumor cell differentiation and perineural invasion. Copyright (c) 2007 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17520682     DOI: 10.1002/cncr.22758

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

Review 1.  Molecular biology of adenoid cystic carcinoma.

Authors:  Jia Liu; Chunbo Shao; Marietta L Tan; David Mu; Robert L Ferris; Patrick K Ha
Journal:  Head Neck       Date:  2011-10-17       Impact factor: 3.147

2.  Stereotactic Radiation for Palliation of Skull Base Recurrences of Salivary Gland Carcinomas: Implications for Tumor Targeting.

Authors:  Zaid A Siddiqui; Edward Melian; Anil Sethi; Vikram C Prabhu; Iris Rusu; Bahman Emami; John P Leonetti; Douglas E Anderson
Journal:  J Neurol Surg B Skull Base       Date:  2016-07-18

3.  Parotid carcinoma: Current diagnostic workup and treatment.

Authors:  Vincent L M Vander Poorten; Francis Marchal; Sandra Nuyts; Paul M J Clement
Journal:  Indian J Surg Oncol       Date:  2010-11-21

4.  Integrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma.

Authors:  Chunbo Shao; Wenyue Sun; Marietta Tan; Chad A Glazer; Sheetal Bhan; Xiaoli Zhong; Carole Fakhry; Rajni Sharma; William H Westra; Mohammad O Hoque; Christopher A Moskaluk; David Sidransky; Joseph A Califano; Patrick K Ha
Journal:  Clin Cancer Res       Date:  2011-05-06       Impact factor: 12.531

5.  Evaluation of MYB promoter methylation in salivary adenoid cystic carcinoma.

Authors:  Chunbo Shao; Weiliang Bai; Jacqueline C Junn; Mamoru Uemura; Patrick T Hennessey; David Zaboli; David Sidransky; Joseph A Califano; Patrick K Ha
Journal:  Oral Oncol       Date:  2011-02-15       Impact factor: 5.337

6.  Quantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumors.

Authors:  Megan L Durr; Wojciech K Mydlarz; Chunbo Shao; Marianna L Zahurak; Alice Y Chuang; Mohammad O Hoque; William H Westra; Nanette J Liegeois; Joseph A Califano; David Sidransky; Patrick K Ha
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

7.  miR-21 regulates tumor progression through the miR-21-PDCD4-Stat3 pathway in human salivary adenoid cystic carcinoma.

Authors:  Lie-Hao Jiang; Ming-Hua Ge; Xiu-Xiu Hou; Jun Cao; Si-Si Hu; Xiao-Xiao Lu; Jing Han; Yi-Chen Wu; Xiang Liu; Xin Zhu; Lian-Lian Hong; Pei Li; Zhi-Qiang Ling
Journal:  Lab Invest       Date:  2015-09-14       Impact factor: 5.662

8.  Aquaporin-1 promoter hypermethylation is associated with improved prognosis in salivary gland adenoid cystic carcinoma.

Authors:  Marietta Tan; Chunbo Shao; Justin A Bishop; Zhaoyong Feng; Bruce J Trock; William H Westra; Patrick K Ha
Journal:  Otolaryngol Head Neck Surg       Date:  2014-02-03       Impact factor: 3.497

9.  Expression of matrix metalloproteinases (MMPs-2, -7, -9, and -26) and tissue inhibitors of metalloproteinases (TIMPs-1 and -2) in pleomorphic adenomas and adenoid cystic carcinomas.

Authors:  Valéria Souza Freitas; Jean Nunes Dos Santos; Pedro Paulo de Andrade Santos; Cassiano Francisco Weege Nonaka; Leão Pereira Pinto; Lélia Batista de Souza
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-10-25       Impact factor: 2.503

10.  miR-200b restoration and DNA methyltransferase inhibitor block lung metastasis of mesenchymal-phenotype hepatocellular carcinoma.

Authors:  W Ding; H Dang; H You; S Steinway; Y Takahashi; H-G Wang; J Liao; B Stiles; R Albert; C B Rountree
Journal:  Oncogenesis       Date:  2012-06-11       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.